Price targets

Analyst ratings

8 analysts rated this company in the past 90 days. The average target price is €110.75, this is a change of +32.5% compared to the current price.

• September 26, 2025

  Berenberg maintains Sanofi's 'Buy' rating - target 110 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Sanofi with a price target of €110. According to her assessment published on Monday, Luisa Hector sees a positive turnaround at the French pharmaceutical company in its research and development sector and raised her forecasts for immunology./rob/edh/ag

  Publication of the original study: September 26, 2025 / 4:27 p.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 25, 2025

  Goldman lowers target for Sanofi to 92 euros - 'Neutral'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has lowered its price target for Sanofi from €94 to €92, but left its rating at "Neutral." James Quigley wrote Thursday evening that the French company's shares have less potential than the European pharmaceutical industry average. The third quarter is likely to have performed as expected./ag/zb

  Publication of the original study: September 25, 2025 / 8:52 p.m. / BST

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 24, 2025

  JPMorgan maintains Sanofi at 'Overweight' - target 105 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Overweight" with a price target of €105. Analyst Richard Vosser expects the third quarter to have been solid, and a confirmation of the company's growth targets underpins market expectations. He wrote this in his outlook for the interim report at the end of October, published on Thursday./rob/ag/gl

  Publication of the original study: September 24, 2025 / 10:34 PM / BST First distribution of the original study: September 25, 2025 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 22, 2025

  JPMorgan maintains Sanofi at 'Overweight' - target 105 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Overweight" with a price target of €105. The FDA's extension of the MS study (nrSPMS) with tolebrutinib is likely to have a slightly negative impact on the market, Richard Vosser wrote on Monday. However, he continues to expect approval, at least initially with regular liver function monitoring./ag/gl

  Publication of the original study: September 22, 2025 / 7:19 a.m. / BST First distribution of the original study: September 22, 2025 / 7:19 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 22, 2025

  Bernstein maintains Sanofi's 'Outperform' rating - target 119 euros

  NEW YORK (dpa-AFX Analyser) - US analyst Bernstein Research has maintained its rating for Sanofi at "Outperform" with a price target of €119. Florent Cespedes wrote on Monday, following the FDA's three-month extension of the MS trial, that the US approval for tolebrutinib is being delayed. This is not unusual. There are apparently questions about possible liver toxicity, but these should be clarified./rob/ag/edh

  Publication of the original study: September 22, 2025 / 6:35 a.m. / UTC

  First distribution of the original study: September 22, 2025 / 6:35 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 17, 2025

  JPMorgan maintains Sanofi at 'Overweight' - target 105 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Overweight" with a price target of €105. New data on Brivekimig for the treatment of inflammatory skin diseases have been positive, wrote Richard Vosser in a study released Wednesday. The current data on the drug, however, did not appear quite as good as those for the competitor Bimzelx./mf/tav

  Publication of the original study: September 17, 2025 / 7:55 a.m. / BST

  First distribution of the original study: September 17, 2025 / 7:55 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 16, 2025

  Berenberg maintains Sanofi's 'Buy' rating - target 110 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Sanofi with a price target of €110. In a study published Wednesday, analyst Luisa Hector includes AstraZeneca, AbbVie, Sanofi, and the recently upgraded Novo Nordisk stock among her buy recommendations. In her analysis, she compared the industry situation with that five years ago, when the valuation was initiated. Innovations in the area of obesity, in particular, have created value since then. Drug prices and the need to offset expiring patents are currently a constant topic. Valuations are at a historic low relative to the market. However, Hector believes the mood among investors is excessively negative./tih/tav

  Publication of the original study: September 16, 2025 / 4:32 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 12, 2025

  Deutsche Bank Research maintains Sanofi's 'Buy' rating - target 110 euros

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Sanofi with a price target of €110. In a study released Friday, Emmanuel Papadakis commented on the results of a third-party rapid survey on initial physician responses to study data on the drug amlitelimab, which have recently been very poorly received by investors. These supported his thesis that the quarterly dosing result was a small plus for Sanofi./tih/mis

  Publication of the original study: September 12, 2025 / Time not specified in the study / CET

  First distribution of the original study: September 12, 2025 / 7:50 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 10, 2025

  JPMorgan maintains Sanofi at 'Overweight' - target 105 euros

  NEW YORK (dpa-AFX Analyst) - Following a conference call with the company's CEO, US bank JPMorgan maintained its rating for Sanofi at "Overweight" with a price target of €105. Paul Hudson commented on several drug candidates, Richard Vosser wrote on Wednesday evening. The CEO expects profitable growth in 2026 thanks to the Amvuttra royalties. Regarding the drug amlitelimab, he highlighted the enormous size of the atopic dermatitis market. Taking the antibody only every twelve weeks (as in the COAST-1 Q12W study) would be a "bonus" and a way to differentiate./tih/ag

  Publication of the original study: September 10, 2025 / 5:51 PM / BST

  First distribution of the original study: September 11, 2025 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 8, 2025

  UBS maintains Sanofi 'Buy' - target 115 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi with a price target of €115. Sanofi is the cheapest major EU pharmaceutical company and is currently trading at a discount of 52 percent to its net asset value and 43 percent to the industry average, Matthew Weston wrote in a study released Tuesday. The French had one of the lowest patent risks in the sector until 2030, but are expected to see a decline for Dupixent starting in 2031./rob/edh/tih

  Publication of the original study: September 8, 2025 / 2:44 PM / GMT

  First distribution of the original study: September 9, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 4, 2025

  Berenberg lowers target for Sanofi to 110 euros - 'Buy'

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has lowered its price target for Sanofi from €118 to €110, but maintained its "Buy" rating. Luisa Hector wrote Thursday evening that the negative price reaction to the study on the drug amlitelimab for the skin disease atopic dermatitis appears excessive and offers a buying opportunity. She considers the results quite good. To achieve the peak sales of €5 billion she expects, only about 20 percent of Dupixent patients would need to be treated with amlitelimab in the future. Hector estimates the probability of a market launch in 2027 at 80 percent./rob/ag/la

  Publication of the original study: September 4, 2025 / 6:12 p.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 4, 2025

  Goldman lowers target for Sanofi to 94 euros - 'Neutral'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs lowered its price target for Sanofi from €100 to €94, but maintained its rating at "Neutral." Analyst James Quigley cut his estimates for the antibody amlitelimab on Thursday evening following its study results. He continues to see question marks surrounding the research pipeline and the compensation for lost Dupixent sales./ag/bek

  Publication of the original study: September 4, 2025 / 9:21 PM / BST

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 4, 2025

  Jefferies maintains Sanofi 'Buy' - target 120 euros

  NEW YORK (dpa-AFX Analyser) - The analysis house Jefferies has left the rating for Sanofi at "Buy" with a price target of 120 euros after a meeting with CFO François Roger. Despite disappointing study data, the company attested to the drug amlitelimab's blockbuster potential, wrote Benjamin Jackson in a study published Thursday./rob/bek/nas

  Publication of the original study: September 4, 2025 / 1:38 PM / Time zone not specified in study

  First distribution of the original study: September 4, 2025 / 1:38 PM / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 4, 2025

  Bernstein maintains Sanofi's 'Outperform' rating - target 119 euros

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Sanofi at "Outperform" with a price target of €119. Analyst Florent Cespedes assessed study data on the drug amlitelimab positively in a study published Thursday. He stated that the drug still has blockbuster potential.

  Publication of the original study: September 4, 2025 / 2:16 p.m. / UTC

  First distribution of the original study: September 4, 2025 / 2:16 p.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 4, 2025

  UBS maintains Sanofi 'Buy' - target 115 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi with a price target of €115. Analyst Matthew Weston elaborated on the results of the study on the drug amlitelimab for the skin disease atopic dermatitis on Thursday morning, given the negative price reaction. Overall, he sees the results as being within the scope of his baseline scenario./rob/ag/la

  Publication of the original study: September 4, 2025 / 7:44 a.m. / GMT First distribution of the original study: September 4, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 4, 2025

  Jefferies maintains Sanofi 'Buy' - target 120 euros

  NEW YORK (dpa-AFX Analyser) - The analyst firm Jefferies has maintained its "Buy" rating for Sanofi with a price target of €120. Amitelimab did not confirm the efficacy of Phase II in Phase III, Benjamin Jackson wrote on Thursday following the antibody's trial data. However, the safety profile could be best-in-class. He also praised the ease of use./rob/ag/gl

  Publication of the original study: September 4, 2025 / 3:35 a.m. / Time zone not specified in the study. First distribution of the original study: September 4, 2025 / 3:35 a.m. / Time zone not specified in the study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 4, 2025

  JPMorgan maintains Sanofi at 'Overweight' - target 105 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Overweight" with a price target of €105. More data on amlitelimab are needed to assess the antibody's potential, Richard Vosser wrote on Thursday following the results of the Coast-1 study, which met its primary endpoint. He expects the shares to underperform significantly during the day, as the reduction in the Eczema Area and Severity Index (EASI-75) was weaker than expected./rob/ag/gl

  Publication of the original study: September 4, 2025 / 7:48 a.m. / BST First distribution of the original study: September 4, 2025 / 7:48 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 26, 2025

  UBS maintains Sanofi 'Buy' - target 115 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi with a price target of €115. Following recent research failures, investors are extremely nervous about the upcoming Phase 3 data for the antibody amlitelimab for atopic dermatitis, Matthew Weston wrote in his outlook on Tuesday evening. The financial market believes the drug will replace a significant portion of Dupixent's profits. However, investors are more optimistic in this regard than he and the analyst consensus. Weston generally recalled that Sanofi has the most dynamic earnings growth measured by core EPS in the European pharmaceutical industry./rob/ag/ajx

  Publication of the original study: August 26, 2025 / 5:41 PM / GMT

  First distribution of the original study: August 27, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 7, 2025

  JPMorgan upgrades Sanofi to 'Overweight' - New target 105 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has upgraded Sanofi from "Neutral" to "Overweight," but lowered its price target from €110 to €105. Since Sanofi is trading at a 20 percent discount to the pharmaceutical sector despite an expected compound annual growth rate of 5 percent in sales and 7 percent in earnings (EPS) through 2030, he considers the current price level a good entry point, wrote Richard Vosser in a study published Friday. Results from Phase III trials offer the potential to restore confidence in the second half of the year./rob/edh/tih

  Publication of the original study: August 7, 2025 / 10:33 PM / BST

  First distribution of the original study: August 8, 2025 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 5, 2025

  Deutsche Bank Research lowers target for Sanofi to 90 euros - 'Hold'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research lowered its price target for Sanofi from €100 to €90 following second-quarter results, but maintained its "Hold" rating. The French pharmaceutical manufacturer performed mixed, Emmanuel Papadakis wrote in a study released Tuesday. Earnings per share fell slightly short of expectations. At least Sanofi has raised the bar for sales this year, as he expected./la/edh

  Publication of the original study: August 5, 2025 / Time not specified in the study / CET. First distribution of the original study: August 5, 2025 / 7:57 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 4, 2025

  UBS maintains Sanofi 'Buy' - target 115 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi after a meeting with management, with a price target of €115. It will take time to analyze the impact of the reductions in certain drug prices demanded by US President Donald Trump, Matthew Weston wrote in a study published Monday./rob/mis/tih

  Publication of the original study: August 4, 2025 / 5:49 a.m. / GMT

  First distribution of the original study: August 4, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 1, 2025

  Bernstein lowers target for Sanofi to 119 euros - 'Outperform'

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research lowered its price target for Sanofi from €124 to €119 following the company's earnings release and maintained its rating at "Outperform." Florent Cespedes wrote in a study released Monday that the pharmaceutical company still has the potential to grow faster than the industry. There are more drivers in the second half of the year. He justified the slightly lower price target with negative exchange rate effects and weak vaccine sales./rob/mis/zb

  Publication of the original study: August 1, 2025 / 6:10 PM / UTC

  First distribution of the original study: August 1, 2025 / 6:10 PM / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 1, 2025

  Bernstein maintains Sanofi at 'Outperform' - Target 124 euros

  NEW YORK (dpa-AFX Analyst) - US analyst Bernstein Research has maintained its rating for Sanofi at "Outperform" with a price target of €124. While the price reductions for many drugs demanded by US President Donald Trump would be a further burden for pharmaceutical companies in addition to the US tariffs, they would also be manageable, wrote Florent Cespedes in a study published Friday. The requested actions appear to be limited to Medicaid. This is a government-funded healthcare program for low-income people, the elderly, and people with disabilities./mis/nas

  Publication of the original study: August 1, 2025 / 7:10 a.m. / UTC

  First distribution of the original study: August 1, 2025 / 7:10 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 28, 2025

  Bernstein maintains Sanofi at 'Outperform' - Target 124 euros

  NEW YORK (dpa-AFX Analyst) - US analyst Bernstein Research has maintained its rating for Sanofi at "Outperform" with a price target of €124. Florent Cespedes wrote in an industry study released Monday that the US would apparently impose tariffs of 15 percent on brand-name drugs, while generics would likely not be affected. Overall, the risks for the companies appear manageable, with the impact on the companies' profits potentially reaching a low- to mid-single-digit percentage. Novo Nordisk would be least affected, and UCB likely most affected./mis/ck

  Publication of the original study: July 28, 2025 / 6:49 a.m. / UTC

  First distribution of the original study: July 28, 2025 / 6:49 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 22, 2025

  Bernstein maintains Sanofi at 'Outperform' - Target 124 euros

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained an "outperform" rating on Sanofi with a price target of €124. The planned acquisition of the British biotech company Vicebio will strengthen the pharmaceutical company's portfolio of vaccines in early development phases and is consistent with its strategy, Florent Cespedes wrote in his commentary on Tuesday./rob/gl/ag

  Publication of the original study: July 22, 2025 / 7:35 a.m. / UTC First distribution of the original study: July 22, 2025 / 7:35 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 17, 2025

  JPMorgan leaves Sanofi at 'Neutral' - Target 110 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained a "neutral" rating on Sanofi with a price target of €110. The figures due at the end of June should demonstrate a solid second quarter, Richard Vosser wrote in his outlook published Thursday. His sales estimate is moderately above the consensus forecast. Vosser also expects the outlook to be raised, which will support the consensus estimates but will not significantly impact them./rob/gl/he

  Publication of the original study: July 17, 2025 / 4:12 PM / BST First distribution of the original study: July 17, 2025 / 4:12 PM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 10, 2025

  UBS maintains Sanofi 'Buy' - target 115 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi with a price target of €115. Matthew Weston adjusted his medium-term estimates in his outlook for the quarterly report on Thursday to reflect current currency forecasts. As with all companies he monitors that report in Swiss francs or euros, the second quarter was likely characterized by massive currency headwinds due to the weak dollar. This is likely to continue to slow sales and earnings growth in the second half of the year and into 2026. However, excluding the currency factor, the French are generally doing well./rob/ag/gl

  Publication of the original study: July 10, 2025 / 7:46 p.m. / GMT. First distribution of the original study: July 11, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 7, 2025

  UBS maintains Sanofi 'Buy' - target 115 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi with a price target of €115. Matthew Weston commented on Tuesday on positive study data from a competitor to Ayvakit from Blueprint Medicines, which was acquired in June. The study therefore has enormous significance for the French company, according to the expert. The efficacy of bezuclastinib compared to Ayvakit – currently the only option for mastocytosis – appears comparable./rob/ag/gl

  Publication of the original study: July 7, 2025 / 5:34 PM / GMT. First distribution of the original study: July 7, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 2, 2025

  Goldman lowers target for Sanofi to 103 euros - 'Neutral'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs lowered its price target for Sanofi from €117 to €103, but maintained its rating at "Neutral." Quarterly results are expected to be largely in line with expectations, James Quigley wrote in his outlook on the report on Wednesday. He sees scope for higher sales targets, but also remaining open pipeline questions./ag/gl

  Publication of the original study: July 2, 2025 / 5:04 PM / BST First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 2, 2025

  Berenberg maintains Sanofi's 'Buy' rating - target 118 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Sanofi with a price target of €118. Luisa Hector recommended buying the stock due to the French pharmaceutical company's promising product pipeline. Following recent mixed news regarding future products, the focus is now on the human monoclonal antibody amiltelimab for use in the treatment of atopic dermatitis. The expert wrote in her commentary published Thursday that she is optimistic about this./rob/bek/ag

  Publication of the original study: July 2, 2025 / 4:35 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 1, 2025

  Barclays lowers target for Sanofi to 115 euros - 'Overweight'

  LONDON (dpa-AFX Analyst) - British investment bank Barclays has lowered its price target for Sanofi from €125 to €115, but maintained its rating at "Overweight." Emily Field adjusted her estimates in her outlook for the quarterly report on Tuesday to reflect recent pipeline setbacks. She expects the results to be "relatively clean."/ag/gl

  Publication of the original study: July 1, 2025 / 7:43 p.m. / GMT First distribution of the original study: July 2, 2025 / 3:00 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 1, 2025

  JPMorgan leaves Sanofi at 'Neutral' - Target 110 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "neutral" ahead of second-quarter results, with a price target of €110. Analyst Richard Vosser expects a solid quarterly report from the French pharmaceutical company. However, adverse exchange rate influences argue against higher consensus estimates, the expert stated in his outlook published on Wednesday./rob/bek/ag

  Publication of the original study: July 1, 2025 / 6:41 PM / BST

  First distribution of the original study: July 2, 2025 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 11, 2025

  Berenberg maintains Sanofi's 'Buy' rating - target 118 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Sanofi with a price target of €118. Luisa Hector wrote in an industry assessment on Wednesday that Novartis and Sanofi are only exposed to limited risks regarding drug prices in the US./ajx/edh

  Publication of the original study: June 11, 2025 / 4:47 p.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 5, 2025

  Jefferies maintains Sanofi 'Buy' - target 120 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Buy" rating for Sanofi with a price target of €120. Benjamin Jackson wrote this in a commentary released Thursday following a roundtable discussion with the French company's sales chief. Management remains enthusiastic about the broad potential of the antibody amlitelimab beyond its core indication of atopic dermatitis./rob/ag/edh

  Publication of the original study: June 5, 2025 / 2:02 AM

  First distribution of the original study: June 5, 2025 / 2:02 AM

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 3, 2025

  Bernstein maintains Sanofi at 'Outperform' - Target 124 euros

  NEW YORK (dpa-AFX Analyst) - US analyst Bernstein Research has maintained its rating for Sanofi at "Outperform" with a price target of €124. "Prevention is always the best medicine," analyst Justin Smith said in his industry commentary published Wednesday, championing vaccines. He wrote that vaccines are expected to continue to be the segment of the biopharmaceutical industry with the highest barriers to entry and the strongest value potential. He therefore forecasts a four percent annual sales increase in this sector through 2034. To benefit from this, he recommends Sanofi and GSK in particular./tih/ag

  Publication of the original study: June 3, 2025 / 8:07 a.m. / UTC

  First distribution of the original study: June 4, 2025 / 4:00 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 3, 2025

  Deutsche Bank Research maintains Sanofi on 'Hold' - Target 100 euros

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Hold" rating for Sanofi, with a price target of €100, in light of the acquisition of the US pharmaceutical company Blueprint. The pharmaceutical company is broadening its revenue base, wrote Emmanuel Papadakis in his commentary published on Tuesday. The terms of the acquisition do not initially appear outrageous, but there are several advantages and disadvantages to consider in the transaction. An initially weak share price reaction to the announcement was not unreasonable./tih/ag

  Publication of the original study: June 3, 2025 / Time not specified in the study / CET

  First distribution of the original study: June 3, 2025 / 7:50 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 2, 2025

  Bernstein maintains Sanofi at 'Outperform' - Target 124 euros

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Sanofi at "outperform" with a price target of €124 in light of the acquisition of Blueprint Medicines. Analyst Florent Cespedes wrote in a report released Monday that the transaction makes sense from a strategic and financial perspective. Business in the areas of rare diseases and immunology would be strengthened./tih/mis

  Publication of the original study: June 2, 2025 / 2:12 PM / UTC

  First distribution of the original study: June 2, 2025 / 2:12 PM / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 2, 2025

  UBS maintains Sanofi 'Buy' - target 115 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi with a price target of €115 in light of the announced acquisition of Blueprint Medicines. The acquisition target is a strategically good fit for the pharmaceutical company and its expertise due to significant overlaps, Jo Walton wrote in a study published Monday. However, the valuation presents a challenge, as it depends heavily on peak sales potential and the sustainability of market shares in the field of systemic mastocytosis (SM)./tih/mis

  Publication of the original study: June 2, 2025 / 10:29 AM / GMT

  First distribution of the original study: June 2, 2025 / 10:29 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 2, 2025

  JPMorgan leaves Sanofi at 'Neutral' - Target 110 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Neutral" with a price target of €110. With the acquisition of Blueprint Medicines, the French company gained access to Ayvakit, which has sales potential of more than $2 billion, Richard Vosser wrote on Monday. Blueprint's analyst, Brian Cheng, has forecast this sales volume for 2030./rob/ag/edh

  Publication of the original study: June 2, 2025 / 9:25 a.m. / BST

  First distribution of the original study: June 2, 2025 / 9:25 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 30, 2025

  Berenberg lowers target for Sanofi to 118 euros - 'Buy'

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg lowered its price target for Sanofi from €120 to €118 following the itepekimab study data, but maintained its "Buy" rating. The price reaction to the mixed study results for the antibody itepekimab was excessive, wrote Luisa Hector in her commentary published on Monday. However, a coherent explanation is needed first. Hector removed itepekimab from its valuation model./rob/ag/zb

  Publication of the original study: May 30, 2025 / 4:27 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 30, 2025

  UBS maintains Sanofi 'Buy' - target 115 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi with a price target of €115. The path to market approval for the COPD antibody itepekimab remains unclear, Jo Walton wrote on Friday following mixed study data. He reduced the probability of success in his valuation model from 60 to 25 percent, but still sees the peak revenue potential in the event of success at $2.5 billion./rob/ag/mis

  Publication of the original study: May 30, 2025 / 9:01 a.m. / GMT

  First distribution of the original study: May 30, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 30, 2025

  JPMorgan leaves Sanofi at 'Neutral' - Target 110 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Neutral" with a price target of €110. Richard Vosser wrote on Friday that the study results for the antibody itepekimab against the lung disease COPD were mixed overall. He considers this a disappointment and expects a delay in market readiness./rob/ag/mis

  Publication of the original study: May 30, 2025 / 8:05 a.m. / BST

  First distribution of the original study: May 30, 2025 / 8:05 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 27, 2025

  Jefferies maintains Sanofi 'Buy' - target 120 euros

  NEW YORK (dpa-AFX Analyser) - The analysis house Jefferies has left Sanofi at "Buy" with a price target of 120 euros. Phase III trials for the key drugs itepekimab, amlietelimab, and tolebrutinib, scheduled for the second half of the year, contain upside potential for the pharmaceutical company, Benjamin Jackson wrote in an outlook published Wednesday./rob/gl/ajx

  Publication of the original study: May 27, 2025 / 2:56 p.m. / Time zone not specified in study. First distribution of the original study: May 27, 2025 / 7:00 p.m. / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 15, 2025

  Berenberg maintains Sanofi's 'Buy' rating - target 120 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained a "Buy" rating on Sanofi with a price target of €120. Under the Inflation Reduction Act (IRA) of US President Donald Trump's predecessor, drug prices for Americans will fall by an average of almost two-thirds starting in January 2026, wrote Kerry Holford in an industry commentary published Friday. This will save the US government around $6 billion, which pharmaceutical companies and insurers would then have to shoulder. The further price reductions demanded by Trump could push these savings up to $10 billion. The mechanism by which Trump intends to achieve this is unclear. However, verbal pressure on the industry could be enough to obtain concessions./gl/edh

  Publication of the original study: May 15, 2025 / 4:13 PM / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 7, 2025

  JPMorgan leaves Sanofi at 'Neutral' - Target 110 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Neutral" with a price target of €110. The French pharmaceutical company expects good growth in 2025 and 2026, wrote Richard Vosser in a study published Thursday./rob/bek/ajx

  Publication of the original study: May 7, 2025 / 12:26 PM / BST

  First distribution of the original study: May 8, 2025 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 28, 2025

  Deutsche Bank Research maintains Sanofi on 'Hold' - Target 100 euros

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Sanofi at "Hold" with a price target of €100. Analyst Emmanuel Papadakis wrote this in a study published Monday following an analyst event on the pharmaceutical company's quarterly results./edh/ck

  Publication of the original study: April 28, 2025 / Time not specified in the study / CEST

  First distribution of the original study: April 28, 2025 / 8:00 a.m. / CEST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 25, 2025

  UBS maintains Sanofi 'Buy' - target 115 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi with a price target of €115 following an investor meeting. Management has developed scenarios regarding import tariffs and described them as manageable, analyst Jo Walton wrote in a report released Monday. Since price increases are difficult to implement, burdens are likely to be offset primarily through cost reductions./bek/nas

  Publication of the original study: April 25, 2025 / 6:54 PM / GMT

  First distribution of the original study: April 25, 2025 / 6:54 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 24, 2025

  Barclays maintains Sanofi at 'Overweight' - target 125 euros

  LONDON (dpa-AFX Analyst) - British investment bank Barclays has maintained its rating for Sanofi at "overweight" with a price target of €125. The French company performed well in the first quarter, analyst Emily Field wrote on Thursday after the report. Contrary to some fears, Dupixent did not disappoint. Although currency developments are increasingly becoming a brake, this is not surprising./ag/tav

  Publication of the original study: April 24, 2025 / 6:48 a.m. / GMT

  First distribution of the original study: April 24, 2025 / 6:48 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 24, 2025

  UBS lowers target for Sanofi to 115 euros - 'Buy'

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS lowered its price target for Sanofi from 120 to 115 euros following the company's earnings release, but maintained its "Buy" rating. The French pharmaceutical company's financial results were solid, and the development of operating costs was favorable, wrote analyst Jo Walton in a study released Friday. The valuation is slightly lower than the industry average./mf/edh

  Publication of the original study: April 24, 2025 / 10:06 PM / GMT

  First distribution of the original study: April 24, 2025 / 10:06 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 24, 2025

  Goldman lowers target for Sanofi to 117 euros - 'Neutral'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has lowered its price target for Sanofi from €122 to €117, but maintained its rating at "Neutral." At first glance, the year has started strongly, wrote analyst James Quigley on Thursday evening following the quarterly report. Upon closer inspection, however, this is primarily due to favorable timing, so there should be no changes to annual estimates. Clear evidence of success must first emerge from the pipeline for momentum to build. Quigley's price target reduction results from currency-related adjustments./ag/jha/

  Publication of the original study: April 24, 2025 / 10:28 PM / BST

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 24, 2025

  Bernstein maintains Sanofi at 'Outperform' - Target 114 euros

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Sanofi at "outperform" with a price target of €114 following its first-quarter results. Analyst Florent Cespedes, in an initial reaction on Thursday, described the pharmaceutical company's robust figures. The company benefited primarily from the dermatitis drug Dupixent and the vaccine business./bek/tav

  Publication of the original study: April 24, 2025 / 6:32 a.m. / UTC

  First distribution of the original study: April 24, 2025 / 6:32 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 16, 2025

  UBS maintains Sanofi 'Buy' - target 120 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained a "buy" rating on Sanofi ahead of the pharmaceutical manufacturer's first-quarter results, with a price target of €120. Analyst Jo Walton wrote in a report released Thursday that he sees a number of important issues. Among other things, he pointed to the impact of the new US administration through potential pharmaceutical tariffs. Sanofi's three most important growth drivers are also likely to be in focus: Dupixent, Altuviiio, and Beyfortus./ck/he

  Publication of the original study: April 16, 2025 / 3:07 p.m. / GMT. First distribution of the original study: April 16, 2025 / 3:07 p.m. / GMT.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 15, 2025

  JPMorgan leaves Sanofi at 'Neutral' - Target 110 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Neutral" with a price target of €110. Study data on the asthma drug amlitelimab are unlikely to have much of an impact on the pharmaceutical company's share price. Analyst Richard Vosser wrote this in a study published Tuesday./bek/gl

  Publication of the original study: April 15, 2025 / 8:18 a.m. / BST First distribution of the original study: April 15, 2025 / 8:18 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 9, 2025

  Jefferies maintains Sanofi 'Buy' - target 120 euros

  NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained a "Buy" rating on Sanofi with a price target of €120. He doesn't predict a bottom yet, but currently sees the best opportunity in five years to buy structural winners, analyst Raj Jilka wrote in a report released Wednesday. He and his team surveyed over 60 industry research teams in Europe to identify 50 market leaders with durable competitive advantages. These leaders are likely to navigate the high market volatility and generate above-average risk-adjusted returns over the long term. Sanofi is well positioned to benefit from the strong growth of the immunology and inflammatory diseases market segment. Important late-stage drugs are also largely ignored./ck/men

  Publication of the original study: April 9, 2025 / 5:44 AM / ET

  First distribution of the original study: April 9, 2025 / 6:00 AM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 4, 2025

  Deutsche Bank Research maintains Sanofi on 'Hold' - Target 100 euros

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Hold" rating for Sanofi with a price target of €100. The French company is also among the candidates with potential for higher annual targets, wrote analyst Emmanuel Papadakis in his outlook for the pharmaceutical industry's reporting season published on Monday./ag/ajx

  Publication of the original study: April 4, 2025 / Time not specified in study / CET

  First distribution of the original study: April 7, 2025 / 8:00 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 3, 2025

  Bernstein maintains Sanofi at 'Outperform' - Target 114 euros

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Sanofi at "Outperform" with a price target of €114. In an industry report released Thursday, analyst Florent Cespedes welcomed the fact that pharmaceutical products are exempt from the comprehensive US tariffs. This is positive for sentiment, after concerns about the consequences of possible import duties had recently weighed on investor sentiment. The consequences for the companies' non-pharmaceutical products should be manageable in the meantime./mis/men

  Publication of the original study: April 3, 2025 / 7:39 a.m. / UTC

  First distribution of the original study: April 3, 2025 / 7:39 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 24, 2025

  JPMorgan leaves Sanofi at 'Neutral' - Target 110 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "neutral" ahead of first-quarter results, with a price target of €110. These figures are likely to be in line with expectations, wrote analyst Richard Vosser in his outlook on Monday evening. The pharmaceutical company's outlook for the current year is also unlikely to change, meaning consensus estimates are likely to remain unchanged despite less favorable exchange rates./bek/ag

  Publication of the original study: March 24, 2025 / 8:36 p.m. / GMT

  First distribution of the original study: March 25, 2025 / 12:15 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 21, 2025

  Goldman starts Sanofi with 'Neutral' - Target 120 euros

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has started its rating of shares of pharmaceutical company Sanofi with a "neutral" rating, with a price target of €120. The French company has proven to be a pipeline story, analyst James Quigley wrote on Friday. However, this has already been priced in, and results are needed to be considered a research leader./ag/la

  Publication of the original study: March 21, 2025 / 6:15 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 11, 2025

  Bernstein maintains Sanofi at 'Outperform' - Target 114 euros

  NEW YORK (dpa-AFX Analyst) - Following a discussion with management, US analyst Bernstein Research has maintained its rating for Sanofi at "Outperform" with a price target of €114. Regarding the issue of US tariffs, the pharmaceutical company is confident that the issue can be managed, wrote analyst Florent Cespedes in a study released Tuesday. Regarding mergers and acquisitions, Sanofi intends to remain financially disciplined and is also well on track to save the targeted two billion euros by 2026./ck/la

  Publication of the original study: March 11, 2025 / 12:14 / UTC

  First distribution of the original study: March 11, 2025 / 12:14 / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 9, 2025

  Jefferies maintains Sanofi 'Buy' - target 120 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained a "Buy" rating on Sanofi with a price target of €120. Further Phase III study results for Amgen's drug Rocatinlimab for atopic dermatitis could rekindle optimism for Sanofi's competitor Amlitelimab, analyst Benjamin Jackson wrote in an assessment released Monday. Amlitelimab is an important drug for the French pharmaceutical company following the expiration of the patent protection for Dupixent./gl/tih

  Publication of the original study: March 9, 2025 / 5:45 PM / ET. First distribution of the original study: March 9, 2025 / 8:01 PM / ET.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 20, 2025

  Bernstein maintains Sanofi at 'Outperform' - Target 114 euros

  NEW YORK (dpa-AFX Analyst) - US analyst Bernstein Research has maintained its rating for Sanofi at "Outperform" with a price target of €114. In an industry study released Thursday, analyst Florent Cespedes refers to the US tariff threats, which also affect pharmaceutical products. According to the World Trade Organization (WTO), pharmaceutical products are considered essential goods and are therefore exempt from tariffs, the expert stated. However, potential collateral damage should be considered. In return, European pharmaceutical companies could invest less money in research in the US, which could reduce US tax revenues in the long term. Furthermore, many US companies produce in Ireland and would therefore also be affected by tariffs. All in all, it remains unclear whether tariffs will even be imposed./mis/edh

  Publication of the original study: February 20, 2025 / 8:54 a.m. / UTC

  First distribution of the original study: February 20, 2025 / 8:54 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 13, 2025

  JPMorgan raises target for Sanofi to 110 euros - 'Neutral'

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan raised its price target for Sanofi from €105 to €110 and maintained its rating at "Neutral." Analyst Richard Vosser wrote in a report released Friday that strong earnings per share (business EPS) for 2025 are underpinned by the pharmaceutical company's growth. However, he expects only a limited, news-driven price impact for the time being./tih/mis

  Publication of the original study: February 13, 2025 / 8:17 PM / GMT

  First distribution of the original study: February 14, 2025 / 12:15 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 13, 2025

  UBS maintains Sanofi 'Buy' - target 120 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi with a price target of €120. The debate surrounding generic versions of Dupixent starting around 2030 will determine developments in the medium term, wrote analyst Jo Walton in a study published Thursday. He disagrees with the skeptics who claim that Sanofi's upcoming immunology products could be intended for medical applications already covered by Dupixent./bek/mis

  Publication of the original study: February 13, 2025 / 4:15 a.m. / GMT

  First distribution of the original study: February 13, 2025 / 4:15 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 2, 2025

  UBS maintains Sanofi 'Buy' - target 120 euros

  ZURICH (dpa-AFX Analyser) - The Swiss major bank UBS has maintained its rating for Sanofi at "Buy" with a price target of 120 euros. Management is very optimistic about the launch of Dupixent for COPD and tolebrutinib for smoldering MS, wrote analyst Jo Walton in his commentary after a round of talks on Monday./ag/mis

  Publication of the original study: February 2, 2025 / 11:14 PM / GMT

  First distribution of the original study: February 2, 2025 / 11:14 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 30, 2025

  UBS raises target for Sanofi to 120 euros - 'Buy'

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has raised its price target for Sanofi from 115 to 120 euros and maintained its "Buy" rating. The fourth quarter was strong, and the share buyback program is exceeding expectations, analyst Jo Walton wrote Thursday evening after a second look at the quarterly report. The drug Dupixent continues to drive high single-digit growth rates. During the conference call, they also expressed confidence in the respiratory medication Beyfortus – despite the competition./ag/mis

  Publication of the original study: January 30, 2025 / 8:43 PM / GMT

  First distribution of the original study: January 31, 2025 / Time not specified in the study / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 30, 2025

  Bernstein maintains Sanofi at 'Outperform' - Target 114 euros

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Sanofi at "outperform" with a price target of €114 following figures for the final quarter of 2024. The pharmaceutical company's results and outlook for 2025 are in line with expectations, wrote analyst Florent Cespedes in a study released Thursday. It confirms that the French are returning to solid growth./mis/nas

  Publication of the original study: January 30, 2025 / 7:42 a.m. / UTC

  First distribution of the original study: January 30, 2025 / 7:42 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 30, 2025

  JPMorgan leaves Sanofi at 'Neutral' - Target 105 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Neutral" with a price target of €105. Despite recent price strength, the French company's shares are likely to post further above-average gains, analyst Richard Vosser wrote on Thursday after the company's results. The outlook and the share buyback program left the consensus with approximately two to three percent room to maneuver./ag/ajx

  Publication of the original study: January 30, 2025 / 7:26 a.m. / GMT

  First distribution of the original study: January 30, 2025 / 7:26 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 30, 2025

  UBS maintains Sanofi 'Buy' - target 115 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi with a price target of €115. Analyst Jo Walton assesses the quarterly report on Thursday as positive "in its initial assessment." The share buyback exceeds expectations./ag/nas

  Publication of the original study: January 30, 2025 / 7:54 a.m. / GMT

  First distribution of the original study: January 30, 2025 / 7:54 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 23, 2025

  JPMorgan leaves Sanofi at 'Neutral' - Target 105 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Neutral" ahead of earnings, with a price target of €105. The market's earnings expectations for 2024 may prove to be somewhat too low, analyst Richard Vosser wrote in a study released Friday. The company's outlook for 2025 should, meanwhile, underpin market expectations./mis/nas

  Publication of the original study: January 23, 2025 / 8:41 PM / GMT

  First distribution of the original study: January 24, 2025 / 12:15 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 22, 2025

  UBS maintains Sanofi 'Buy' - target 115 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi with a price target of €115. Analyst Jo Walton considers Sanofi's shares to be one of the most attractive in the European pharmaceutical sector heading into 2025. The stock came under considerable pressure in the fourth quarter and is now trading at a significant discount compared to its major European peers, he wrote in his outlook published Thursday. He expects, among other things, the announcement of share buyback plans when the figures are presented at the end of January./ck/ag

  Publication of the original study: January 22, 2025 / 10:17 PM / GMT

  First distribution of the original study: January 22, 2025 / 10:17 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 16, 2025

  JPMorgan leaves Sanofi at 'Neutral' - Target 105 euros

  NEW YORK (dpa-AFX Analyst) - Following a pharmaceutical conference, US bank JPMorgan maintained its rating for Sanofi at "Neutral" with a price target of €105. The pharmaceutical company will announce details of its planned share buyback when it releases its quarterly figures at the end of January, analyst Richard Vosser wrote in a report released Thursday. Operationally, the focus remains on immunology and rare diseases./bek/tav

  Publication of the original study: January 16, 2025 / 02:20 / GMT

  First distribution of the original study: January 16, 2025 / 02:20 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 6, 2025

  Berenberg maintains Sanofi's 'Buy' rating - target 115 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Sanofi with a price target of €115. With regard to the industry, company-specific pressures in China are likely to ease in the new year, and valuation pressure on companies active in the US vaccine market is also likely to ease, wrote analyst Luisa Hector in an industry study published Tuesday. The latter is because the Trump administration is unlikely to be able to implement all of its election campaign plans. In addition, drugs and drug candidates for obesity remained an important topic./mis/zb

  Publication of the original study: January 6, 2025 / 6:03 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 6, 2025

  Bernstein maintains Sanofi at 'Outperform' - Target 114 euros

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Sanofi at "Outperform" with a price target of €114. Although concerns about potential burdens from the Trump administration's healthcare policy have weighed somewhat on the European pharmaceutical sector towards the end of 2024, analyst Florent Cespedes remains optimistic in the medium term in a 2025 outlook published Tuesday. The reasons include good growth prospects given demographic developments and the industry's innovative strength, attractive stock valuations overall, and cash generation. His favorites are AstraZeneca, followed by Sanofi and Novartis./mis/bek

  Publication of the original study: January 6, 2025 / 5:00 a.m. / UTC

  First distribution of the original study: January 7, 2025 / 5:21 p.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 17, 2024

  Jefferies maintains Sanofi 'Buy' - target 120 euros

  NEW YORK (dpa-AFX Analyser) - The analysis house Jefferies has left the rating for Sanofi at "Buy" with a price target of 120 euros following new study data on the antibody Duvakitug. The positive Phase IIb results in ulcerative colitis and Crohn's disease are encouraging, wrote analyst Peter Welford in a study published Tuesday./edh/tih

  Publication of the original study: December 17, 2024 / 8:12 a.m. / ET

  First distribution of the original study: December 17, 2024 / 8:12 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 17, 2024

  JPMorgan leaves Sanofi at 'Neutral' - Target 105 euros

  NEW YORK (dpa-AFX Analyser) - The US bank JPMorgan has left its rating for Sanofi at "Neutral" with a price target of 105 euros following new study data on the antibody Duvakitug. Given the strong efficacy data in both ulcerative colitis and Crohn's disease, Sanofi shares are likely to gain a few percentage points in the short term, wrote analyst Richard Vosser in an initial reaction published on Tuesday./edh/tih

  Publication of the original study: December 17, 2024 / 3:14 PM / GMT

  First distribution of the original study: December 17, 2024 / 3:14 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 6, 2024

  Deutsche Bank Research maintains Sanofi at 'Sell' - target 85 euros

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained a "sell" rating on Sanofi with a price target of €85. Discussions with the pharmaceutical company at a Deutsche Bank event revealed both positive and negative aspects regarding the company's business prospects, analyst Emmanuel Papadakis wrote in a commentary published Friday. Overall, the positive aspects outweigh the negative ones with regard to sales growth, margin prospects, and the French company's confidence in being able to cope with the expiration of the patent for Dupixent in 2031 in the long term./gl/nas

  Publication of the original study: December 6, 2024 / 8:05 a.m. / CET First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 3, 2024

  Deutsche Bank Research lowers target for Sanofi to 85 euros - 'Sell'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has lowered its price target for Sanofi from €90 to €85 and maintained its rating at "Sell." Analyst Emmanuel Papadakis wrote this in his commentary published Tuesday on the prescription trends for the pharmaceutical company's key drugs in the week ending November 22.

  Publication of the original study: December 3, 2024 / 8:03 a.m. / CET. First distribution of the original study: Date not specified in study / Time not specified in study / CET.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 2, 2024

  JPMorgan raises target for Sanofi to 105 euros - 'Neutral'

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan raised its price target for Sanofi from €100 to €105, but maintained its rating at "Neutral." The coming year is likely to be characterized by innovations in product pipelines for European pharmaceutical companies, given the expiration of several important patents, analyst Richard Vosser wrote in an outlook published Tuesday. His preferred industry giants are Novo Nordisk and AstraZeneca, and from the life sciences sector, Merck KGaA, among others. Sanofi is also likely to offer some innovations. However, the more important ones are likely to come in 2026/27. Vosser, however, does not expect any successful new products at Roche and little news at GSK./gl/ag

  Publication of the original study: December 2, 2024 / 8:11 p.m. / GMT. First distribution of the original study: December 3, 2024 / 12:15 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 28, 2024

  UBS maintains Sanofi 'Buy' - target 110 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi with a price target of €110. Analyst Jo Walton praised the French company's strong growth profile in his second review of the quarterly report on Monday, noting this is important for a re-evaluation./ag/mis

  Publication of the original study: October 28, 2024 / 7:58 a.m. / GMT

  First distribution of the original study: October 28, 2024 / 7:58 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 25, 2024

  UBS maintains Sanofi 'Buy' - target 110 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi following third-quarter results, with a price target of €110. Analyst Jo Walton ventured an "initial diagnosis" in a study released Friday. He wrote that sales exceeded his and consensus estimates, driven in part by vaccine sales./tih/edh

  Publication of the original study: October 25, 2024 / 7:30 a.m. / GMT

  First distribution of the original study: October 25, 2024 / 7:30 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 21, 2024

  UBS maintains Sanofi 'Buy' - target 110 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Sanofi at "Buy" with a price target of €110 in light of the planned sale of its majority stake in the consumer division Opel. Analyst Jo Walton welcomes more clarity regarding divestments of parts of the group in a study released Monday. Sanofi expects cash proceeds in the high single-digit billion range./tih/ajx

  Publication of the original study: October 21, 2024 / 10:23 / GMT

  First distribution of the original study: October 21, 2024 / 10:23 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 21, 2024

  JPMorgan leaves Sanofi at 'Neutral' - Target 100 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Neutral" with a price target of €100. The announced partial sale of the consumer business Opella for €16 billion would be better than expected, analyst Richard Vosser wrote in a study released Monday. However, uncertainty remains regarding the extent of a potential share buyback./ajx

  Publication of the original study: October 21, 2024 / 8:17 a.m. / BST

  First distribution of the original study: October 21, 2024 / 8:44 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 21, 2024

  Jefferies maintains Sanofi 'Buy' - target 120 euros

  NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained its rating for Sanofi at "Buy" with a price target of €120. If the majority stake in the consumer business, called Opella, is sold to US investor CD&R, this would likely dilute Sanofi's earnings per share by an estimated 10 percent, wrote analyst Peter Welford in a study released Monday. However, any share buybacks with the proceeds are not yet taken into account./bek/mis

  Publication of the original study: October 21, 2024 / 2:48 a.m. / ET

  First distribution of the original study: October 21, 2024 / 2:48 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 18, 2024

  JPMorgan leaves Sanofi at 'Neutral' - Target 100 euros

  NEW YORK (dpa-AFX Analyser) - The US bank JPMorgan has left its rating for Sanofi at "Neutral" with a price target of 100 euros. Phase IIb/III data on clesrovimab confirm a weaker efficacy profile in RSV infections, although efficacy in preventing hospitalizations is as expected, analyst Richard Vosser wrote in a study published Friday./mis/la

  Publication of the original study: October 18, 2024 / 8:03 a.m. / BST First distribution of the original study: October 18, 2024 / 8:21 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 18, 2024

  Berenberg maintains Sanofi's 'Buy' rating - target 115 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Sanofi with a price target of €115. The pharmaceutical company's current valuation is highly attractive, meaning investors are getting the drug development practically for free, wrote analyst Luisa Hector in a study published Friday./edh/la

  Publication of the original study: October 18, 2024 / 5:44 a.m. / GMT First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 17, 2024

  UBS maintains Sanofi 'Buy' - target 110 euros

  ZURICH (dpa-AFX Analyst) - The Swiss major bank UBS has maintained its rating for Sanofi at "Buy" with a price target of 110 euros ahead of the quarterly figures expected on October 25. He will pay particular attention to the sustainability of the blockbuster drug Dupixent and the acceptance of the drug Beyfortus, wrote analyst Jo Walton in a study published Thursday./ck/bek

  Publication of the original study: October 17, 2024 / 6:47 a.m. / GMT

  First distribution of the original study: October 17, 2024 / 6:47 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 17, 2024

  UBS maintains Sanofi 'Buy' - target 110 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Sanofi ahead of earnings, with a price target of €110. The atopic dermatitis drug Dupixent is likely to have once again been the growth driver for the French pharmaceutical company in the third quarter, analyst Carl Walton wrote in a study released Friday. Growth should then accelerate in 2025./mf/edh

  Publication of the original study: October 17, 2024 / 6:47 a.m. / GMT

  First distribution of the original study: October 17, 2024 / 6:47 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 17, 2024

  JPMorgan leaves Sanofi at 'Neutral' - Target 100 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Neutral" with a price target of €100 ahead of third-quarter results. Analyst Richard Vosser wrote in a report released Thursday that his earnings per share (EPS) estimate is above market expectations. Overall, the French pharmaceutical company appears to have performed solidly. The expert continues to expect a moderate forecast increase.

  Publication of the original study: October 17, 2024 / 2:56 PM / BST First distribution of the original study: October 17, 2024 / 3:03 PM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 16, 2024

  Deutsche Bank Research maintains Sanofi at 'Sell' - target 90 euros

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Sanofi at "Sell" with a price target of €90. Analyst Emmanuel Papadakis examined the pharmaceutical company's appearance at the annual congress for infectious diseases, IDweek, in a study published Wednesday./edh/bek

  Publication of the original study: October 16, 2024 / Time not specified in the study / CET

  First distribution of the original study: October 16, 2024 / 08:02 / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 10, 2024

  Deutsche Bank Research raises target for Sanofi to 90 euros - 'Sell'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research raised its price target for Sanofi from €85 to €90, but maintained its "sell" rating. The US approval of Dupixent at the end of September is clearly positive news for the pharmaceutical company, wrote analyst Emmanuel Papadakis in a commentary published Thursday. However, it remains questionable whether expectations for the atopic dermatitis drug for 2025 will therefore rise./gl/ag

  Publication of the original study: October 10, 2024 / 8:05 a.m. / CET First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 2, 2024

  JPMorgan leaves Sanofi at 'Neutral' - Target 100 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Neutral" with a price target of €100. The third quarter is likely to slightly disappoint expectations, wrote analyst Richard Vosser in his outlook for the report published Thursday. Nevertheless, slightly higher annual targets for the pharmaceutical company should already be included in the consensus./ag/edh

  Publication of the original study: October 2, 2024 / 10:48 PM / BST

  First distribution of the original study: October 3, 2024 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 20, 2024

  JPMorgan leaves Sanofi at 'Neutral' - Target 100 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan maintained its rating for Sanofi Ectrims at "Neutral" with a price target of €100 at the Multiple Sclerosis Congress. Phase III data from the Hercules trial in secondary progressive multiple sclerosis (SPMS) showed a strong benefit, similar to studies in relapsing-remitting multiple sclerosis (RMS), analyst Richard Vosser wrote in a study released Friday. Strong data should ultimately support the path to a potential market launch.

  Publication of the original study: September 20, 2024 / 11:51 AM / BST First distribution of the original study: September 20, 2024 / 11:56 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 9, 2024

  Berenberg raises target for Sanofi to 115 euros - 'Buy'

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has raised its price target for Sanofi from €105 to €115 and maintained its rating at "Buy." Thanks to increased research and development spending, the pharmaceutical company is generating higher revenues, wrote analyst Luisa Hector in a commentary published on Tuesday. The stock is also very attractively valued./gl/ag

  Publication of the original study: September 9, 2024 / 4:49 p.m. / GMT First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 3, 2024

  Deutsche Bank Research maintains Sanofi at 'Sell' - target 85 euros

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Sanofi at "Sell" with a price target of €85. The pharmaceutical company's challenging pipeline was a decisive factor in its fundamentally cautious assessment, wrote analyst Emmanuel Papadakis in a study released Tuesday. The partial success now achieved with the MS drug tolebrutinib could be seen as a success by some, given the lowered expectations, but Papadakis warned against excessive optimism./ajx/ngu

  Publication of the original study: September 3, 2024 / Time not specified in study / CET. First distribution of the original study: September 3, 2024 / 7:52 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 2, 2024

  Jefferies maintains Sanofi 'Buy' - target 120 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained a "Buy" rating on Sanofi with a price target of €120. Phase III clinical trial results for the multiple sclerosis drug tolebrutinib were mixed but as expected, analyst Peter Welford wrote in a report released Monday. Nevertheless, the risks have largely been eliminated, and perhaps even sales of one to two billion US dollars for the pharmaceutical company with the drug are possible. The current consensus estimate for 2028 is €542 million, and its forecast is €860 million./gl/ajx

  Publication of the original study: September 2, 2024 / 2:50 a.m. / ET. First distribution of the original study: September 2, 2024 / 2:50 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 2, 2024

  Bernstein maintains Sanofi at 'Outperform' - Target 114 euros

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Sanofi at "outperform" with a price target of €114. In a study published Tuesday, analyst Florent Cespedes highlighted the pharmaceutical company's positive results with the drug tolebrutinib in the field of progressive multiple sclerosis (SPMS). As his preferred "value stock," Sanofi is returning to growth./tih/gl

  Publication of the original study: September 2, 2024 / 11:20 PM / UTC. First distribution of the original study: September 3, 2024 / 4:01 AM / UTC.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 2, 2024

  Berenberg maintains Sanofi's 'Buy' rating - target 105 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Sanofi with a price target of €105. The Phase III clinical trial results for the multiple sclerosis drug tolebrutinib exceeded investors' expectations, analyst Luisa Hector wrote in a study published Tuesday. However, it only slightly increased the net present value (NPV) for the product, as the probability of market launch is now higher, but at the same time it assumes a lower peak sales potential./ck/ngu

  Publication of the original study: September 2, 2024 / 4:24 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 2, 2024

  Stifel maintains Sanofi 'Buy' - target 111 euros

  FRANKFURT (dpa-AFX Analyst) - Investment bank Stifel has maintained its "Buy" rating for Sanofi following study data on the drug tolebrutinib in two therapeutic areas, with a price target of €111. The results were positive in one study, but primary endpoints were missed in two others, analyst Eric Le Berrigaud wrote in a study released Monday. However, the positive result in the area of secondary progressive multiple sclerosis (SPMS) is a real success, as there is a potential for a real blockbuster here, as no other small-molecule inhibitor is currently being investigated for use against SPMS./tih/ck

  Publication of the original study: September 2, 2024 / 2:10 a.m. / EDT

  First distribution of the original study: September 2, 2024 / 2:10 a.m. / EDT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 2, 2024

  JPMorgan leaves Sanofi at 'Neutral' - Target 100 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Sanofi at "Neutral" with a price target of €100. While the drug tolebrutinib missed its targets in relapsing-remitting multiple sclerosis (RMS), as expected, there has been encouraging success in the area of secondary progressive multiple sclerosis (SPMS), analyst Richard Vosser wrote in a study released Monday. However, further details are still needed./tih/ajx

  Publication of the original study: September 2, 2024 / 7:26 a.m. / BST

  First distribution of the original study: September 2, 2024 / 7:26 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.